Christopher Paa, MD
Cardiovascular Disease · Sioux Falls, SDNPI 1265486138
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,996 of the $3,095 with a category attached, or 64.5%. Abbott accounts for 95.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $1,962 and has fallen 93.1% since, to $135 in 2025.
Across 27 payments — averaging $114.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Edwards Lifesciences$135
- Medtronic$12
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1
Across 5 payments — averaging $2608.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$9K
- AstraZeneca$4K
What the payments were for
- Travel & lodging$1,99664%
- Food & beverage$1,09936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 24 | $2,947 |
| Edwards Lifesciences | 1 | $135 |
| Medtronic | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,095 in reported general payments places this provider in the 65th percentile of 33 cardiovascular disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndaqelTafamidis Meglumine | 29 | $767,840 |
| EliquisApixaban | 203 | $164,242 |
| Repatha SureclickEvolocumab | 105 | $61,233 |
| XareltoRivaroxaban | 45 | $46,229 |
| EntrestoSacubitril/Valsartan | 36 | $29,109 |
| FarxigaDapagliflozin Propanediol | 20 | $20,447 |
| Repatha SyringeEvolocumab | 13 | $7,331 |
| Praluent PenAlirocumab | 13 | $6,165 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $2,714 |
| Flecainide Acetate | 54 | $2,696 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 64 | $1,930 |
| Metoprolol Succinate | 146 | $1,351 |
| Atorvastatin Calcium | 105 | $1,204 |
| Rosuvastatin Calcium | 117 | $1,125 |
| Carvedilol | 201 | $948 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Sioux Falls
- Naveen RajpurohitSioux Falls$68K
- Kevin VaskaSioux Falls$24K
- Udit BhatnagarSioux Falls$19K
- John BacharachSioux Falls$18K
- Mahmoud SharafSioux Falls$11K
- Maria StysSioux Falls$3K
- Richard ClarkSioux Falls$2K
- Amjad Panickaveettil Mohamed BasheerSioux Falls$1K
- Fawzi AmeerSioux Falls$1K
- Sherrie BrooksSioux Falls$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.